Skip to main content

Table 5 Risk factors for cannulation failure

From: Duodenal major papilla morphology can affect biliary cannulation and complications during ERCP, an observational study

  Univariate analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
Papilla
 1 ref. ref.
 2 7.91 (1.25–50.12) 0.028* 7.18 (1.05–49.19) 0.045*
 3 7.25 (1.46–36.04) 0.015* 7.44 (1.45–38.28) 0.016*
 4 3.87 (0.73–20.44) 0.111 3.19 (0.58–17.43) 0.181
PAD
 0 ref.   
 2 0.74 (0.16–3.42) 0.695   
 3 0.28 (0.06–1.27) 0.099   
Indication
 Stone ref. ref.
 Cancer 3.25 (1.10–9.64) 0.033* 4.45 (1.35–14.66) 0.014*
 Other 1.59 (0.33–7.72) 0.567 2.60 (0.47–14.23) 0.271
Diabetes 0.35 (0.08–1.57) 0.172   
Hypertension 0.83 (0.31–2.25) 0.715   
CVA 3.39 (0.88–13.01) 0.075   
CRI 0.56 (0.07–4.39) 0.581   
COPD 4.99 (0.95–26.13) 0.057   
CAD 0.93 (0.12–7.41) 0.943   
Cirrhosis 0.00 (0.00- 0.999   
Age 1.05 (1.01–1.09) 0.010* 1.06 (1.01–1.11) 0.010*
Gender-Male 0.79 (0.30–2.12) 0.647   
Platelet 1.00 (0.99–1.00) 0.297   
PT 1.29 (1.00–1.66) 0.054   
APTT 1.07 (0.99–1.16) 0.083   
AST 1.00 (1.00–1.00) 0.429   
ALT 1.00 (1.00–1.00) 0.346   
Bilirubin 1.03 (0.95–1.12) 0.469   
Creatinine 1.06 (0.59–1.89) 0.851   
  1. Logistic regression. *p < 0.05, **p < 0.01
  2. CVA Cerebral vascular disease, CRI Chronic renal insufficiency, COPD Chronic obstructive pulmonary disease, CAD Coronary artery disease, PT Prothrombin Time, APTT Activated Partial Thromboplastin Time, AST Aspartate transaminase, ALT Alanine transaminase, PAD Periampullary diverticulum